Summer 2026
Posted on 8/1/2025
Medical device maker advancing therapies
$29 - $33.25/hr
No H1B Sponsorship
North Haven, CT, USA + 2 more
More locations: Lafayette, CO, USA | Minneapolis, MN, USA
Hybrid
Interns must work a minimum of 4 days a week onsite.
| , , , , |
Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.
Company Size
10,001+
Company Stage
IPO
Headquarters
Fridley, Minnesota
Founded
1949
People at Medtronic who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Employee Assistance Program
Wellness Program
Medtronic launches PulseSelect PFA system in India. Recently, Medtronic expanded its cardiac portfolio by introducing the PulseSelect system in India. Consequently, Indian cardiologists now have access to this next-generation pulsed field ablation technology to treat atrial fibrillation. Atrial fibrillation remains a severely underdiagnosed heart rhythm disorder that affects millions of people across the country. However, traditional thermal therapies like radiofrequency ablation often carry a small risk of collateral tissue damage. To solve this issue, the novel system delivers short electrical pulses instead of extreme heat or cold. This non-thermal mechanism successfully isolates the pulmonary veins while protecting nearby sensitive structures. How Pulsed Field Ablation enhances patient safety. Specifically, the system targets cardiac cells using a high-voltage electrical field. Because it avoids thermal energy, it prevents injury to the esophagus and surrounding nerves. Therefore, physicians can perform the procedure more safely and quickly than before. In addition, clinical studies have already demonstrated the system's exceptional safety profile globally. Meanwhile, Indian hospitals are already integrating this breakthrough into their routine electrophysiology workflows. Addressing the Growing Burden of AFib in India. India is witnessing a significant rise in stroke cases and complex cardiac diseases. As a result, expanding advanced therapeutic options is critical for improving patient outcomes. Furthermore, many patients ignore mild symptoms, which unfortunately delays their diagnosis and care. Medtronic aims to bridge this care gap by supporting healthcare providers with high-precision tools. Ultimately, this innovation will help reduce stroke risks and enhance the overall quality of life for those pursuing an advanced career in cardiology. Frequently asked questions. Q1: What is pulsed field ablation? Pulsed field ablation is a non-thermal cardiac ablation technique that uses controlled electrical pulses to target abnormal heart tissue while sparing adjacent structures. Q2: How does the PulseSelect system reduce procedural risks? The device avoids extreme temperatures, which significantly lowers the risk of damaging nearby tissues like the esophagus or phrenic nerve. References * Medtronic launches device to treat atrial fibrillation - ETHealthworld * Medtronic Introduces PulseSelect(TM) PFA Technology to address India's Growing AFib and Stroke Burden - Medtronic Press Release * Kauvery Hospitals Launches Advanced Pulsed Field Ablation Systems in Chennai for Atrial Fibrillation Treatment in Tamil Nadu - ANI News Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.
Congratulations to Dr. Katharina Mitchell on successfully completing her first AltaViva implant! At Idaho Urologic Institute and Surgery Centr of Idaho, Idurology is committed to offering innovative treatment options that improve the quality of life for its patients. Idurology is proud to have several urologists trained in this advanced therapy, expanding access to care for patients experiencing overactive bladder and related urinary conditions. Idurology is grateful for its partnership with Medtronic and the opportunity to bring leading-edge technology and treatment options to the communities Idurology serve. Collaborations like these help ensure its patients have access to the latest advancements in urologic care close to home. Thank you to everyone involved in supporting this milestone. Idurology look forward to continuing to grow these services and helping more patients find relief and improve their daily lives.
Medtronic invests in two ICE catheter technology companies
Medtronic and GE HealthCare have launched a digital integration combining GE's bkActiv intraoperative ultrasound with Medtronic's Stealth AXiS surgical navigation system for cranial neurosurgery. The commercially available system provides real-time imaging during procedures, connecting Medtronic's navigation and robotics platforms with GE HealthCare's imaging technology. The integration aims to enhance clinical decision-making during complex cranial procedures through precise guidance and visualisation. It may influence hospital equipment purchasing decisions, surgeon productivity and operating room efficiency. Medtronic currently trades at $87.91, approximately 19.8% below the $109.64 analyst target range midpoint. The stock has experienced a 2.2% decline over the past 30 days. Adoption rates amongst surgeons and hospitals, alongside hospital capital spending on neurosurgery suites, will be key factors to monitor.
GE HealthCare has announced a digital integration between its bkActiv intraoperative ultrasound system and Medtronic's Stealth AXiS surgical navigation system, now commercially available for cranial procedures. The integration allows neurosurgeons to use bkActiv as a plug-and-play real-time visualisation solution during procedures. The system addresses "brain shift", a natural movement of the brain during surgery that reduces pre-surgical image accuracy. bkActiv provides live ultrasound images alongside pre-operative MRI or CT scans on the Stealth AXiS system, recently cleared by the FDA for cranial procedures in the United States. Features include sterilisable transducers, sensitive colour Doppler for blood flow visualisation, and remote control capability from the sterile field. The companies will showcase the integration at the American Association of Neurological Surgeons Annual Scientific Meeting in May 2026.